Treatment of Obesity and Diabetes Using Oxytocin or Analogs in Patients and Mouse Models

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Hai ^a   Wu, Chenguang ^b   Chen, Qiaofen ^b   Chen, Xiaoluo ^b   Xu, Zhigang ^b   Wu, Jing ^b   Cai, Dongsheng ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN; OXYTOCIN DERIVATIVE; PLACEBO; SODIUM CHLORIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CONTROL;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; OBESITY; OXYTOCIN; PILOT PROJECTS; PREDIABETIC STATE; YOUNG ADULT;

EID: 84877881984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061477     Document Type: Article

References (38)

1. Briones M, Bajaj M, (2006) Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. Expert Opin Pharmacother 7: 1055-1064.
2. Amori RE, Lau J, Pittas AG, (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206.
3. Purnell JQ, Flum DR, (2009) Bariatric surgery and diabetes: who should be offered the option of remission? JAMA 301: 1593-1595.
4. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, et al. (2012) Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366: 1567-1576.
5. Mingrone G, Panunzi S, De GA, Guidone C, Iaconelli A, et al. (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366: 1577-1585.
6. Laferrere B, Teixeira J, McGinty J, Tran H, Egger JR, et al. (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 2479-2485.
7. Soloff MS, Alexandrova M, Fernstrom MJ, (1979) Oxytocin receptors: triggers for parturition and lactation? Science 204: 1313-1315.
8. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, et al. (2000) Social amnesia in mice lacking the oxytocin gene. Nat Genet 25: 284-288.
9. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E, (2005) Oxytocin increases trust in humans. Nature 435: 673-676.
10. Donaldson ZR, Young LJ, (2008) Oxytocin, vasopressin, and the neurogenetics of sociality. Science 322: 900-904.
11. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, et al. (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 107: 4389-4394.
12. Bartz JA, Zaki J, Ochsner KN, Bolger N, Kolevzon A, et al. (2010) Effects of oxytocin on recollections of maternal care and closeness. Proc Natl Acad Sci U S A 107: 21371-21375.
13. Ishak WW, Kahloon M, Fakhry H, (2011) Oxytocin role in enhancing well-being: a literature review. J Affect Disord 130: 1-9.
14. Zhang G, Bai H, Zhang H, Dean C, Wu Q, et al. (2011) Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 69: 523-535.
15. Zhang G, Cai D, (2011) Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab 301: E1004-E1012.
16. Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, et al. (2012) Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 302: E134-E144.
17. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, et al. (2011) Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One 6: e25565.
18. Zhang X, Zhang G, Zhang H, Karin M, Bai H, et al. (2008) Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135: 61-73.
19. Kubosaki A, Nakamura S, Notkins AL, (2005) Dense core vesicle proteins IA-2 and IA-2beta: metabolic alterations in double knockout mice. Diabetes 54Suppl 2: S46-S51.
20. Forood B, Feliciano EJ, Nambiar KP, (1993) Stabilization of alpha-helical structures in short peptides via end capping. Proc Natl Acad Sci U S A 90: 838-842.
21. Yamanaka T, Hase S, Sakakibara S, Schwartz IL, Dubois BM, et al. (1970) Crystalline deamino-dicarba-oxytocin. Preparation and some pharmacological properties. Mol Pharmacol 6: 474-480.
22. Tsuji A, (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2: 54-62.
23. Banks WA, (2006) The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 3: 707-712.
24. Barrera CM, Kastin AJ, Banks WA, (1987) D-[Ala1]-peptide T-amide is transported from blood to brain by a saturable system. Brain Res Bull 19: 629-633.
25. Zlokovic BV, Hyman S, McComb JG, Lipovac MN, Tang G, et al. (1990) Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta 1025: 191-198.
26. Banks WA, Kastin AJ, Coy DH, (1984) Evidence that [125I]N-Tyr-delta sleep-inducing peptide crosses the blood-brain barrier by a non-competitive mechanism. Brain Res 301: 201-207.
27. Wilson JF, (1988) Low permeability of the blood-brain barrier to nanomolar concentrations of immunoreactive alpha-melanotropin. Psychopharmacology (Berl) 96: 262-266.
28. Kublaoui BM, Gemelli T, Tolson KP, Wang Y, Zinn AR, (2008) Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol Endocrinol 22: 1723-1734.
29. Sabatier N, Caquineau C, Dayanithi G, Bull P, Douglas AJ, et al. (2003) Alpha-melanocyte-stimulating hormone stimulates oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. J Neurosci 23: 10351-10358.
30. Siljee JE, Unmehopa UA, Kalsbeek A, Swaab DF, Fliers E, et al. (2013) Melanocortin 4 receptor distribution in the human hypothalamus. Eur J Endocrinol 168: 361-369.
31. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB, (2005) Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 493: 63-71.
32. Morton GJ, (2007) Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 583: 437-443.
33. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M, (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12: 524-538.
34. Feifel D, (2012) Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 37: 304-305.
35. Nuevo R, Chatterji S, Fraguas D, Verdes E, Naidoo N, et al. (2011) Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry 72: 1592-1599.
36. Peet M (2004) Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl 47: S102-S105.
37. Mai Q, Holman CD, Sanfilippo FM, Emery JD, Preen DB, (2011) Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med 9: 118.
38. Leonard BE, Schwarz M, Myint AM, (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 26: 33-41.